Zerit

61 ; Patent of addition to Application No. : Filed on: 62 ; Divisional to Applcation No.: Filed on: 57 ; Abstract A novel process for the preparation of + ; - 3R, 5S ; -7-[4- 4-Fluorophenyl ; -6-isopropyl- 2- N -methyl -N methanesulfonylamino ; pyrimidin -5-yl] -3, 5-dihydroxy -6- E ; -heptenoic acid calcium salt 2: 1 ; . novel process for the preparation of a compound of formula. We believe ADXS.OB "now" has a solid investment potential and significant upside with encouraging initial clinical results of "Lm"; recent peer reviewed abstracts s strong patent position and Thomas Moore as the CEO 12 06 ; , as well as the closing 10 07 ; of .4 m financing. We have modeled a valuation of .08 and believe ADXS.OB is now a solid investment with significant upside. CLASS: fi xed dose combination--nucleoside analogs also called nucleoside reverse transcriptase inhibitors, NRTIs or nukes ; STANDARD DOSE: One tablet 150 mg Epivir 3TC lamivudine, 300 mg Retrovir AZT zidovudine ; , twice-a-day 12 hours apart ; , with no food restrictions may be taken with or without food ; . Take missed dose as soon as possible, but do not double up on your next dose. AWP: 1.83 month MANUFACTURER CONTACT: GlaxoSmithKline, combivir , 1 888 ; 8255249 AIDSINFO: 1 800 ; HIV0440 4480440 ; , aidsinfo.nih.gov POTENTIAL SIDE EFFECTS AND TOXICITY: May be taken with food to decrease potential nausea associated with AZT. See drug pages for lamivudine, 3TC Epivir ; and zidovudine, AZT Retrovir ; for more details. POTENTIAL DRUG INTERACTIONS: See lamivudine, 3TC Epivir ; and zidovudine, AZT Retrovir ; . Do not take Retrovir or Epivir while taking Combivir since these medications are already in Combivir. TIPS: Combivir has been shown in multiple clinical trials to be a potent regimen with either a protease inhibitor or NNRTI. It is the combination of lamivudine, 3TC Epivir ; and zidovudine, AZT Retrovir ; into one pill; see the pages of those individual drugs for more information. The AZT in Combivir can cause fatigue and anemia--it isn't pretty in those at risk for developing anemias see Retrovir ; . One head-to-head study against Truvada found greater toxicity with Combivir, due to anemia. But Combivir is still the most proven dual-nuke combo and every doctor out there should be comfortable with managing its side effects. Combivir brings with it one of the "T" drugs, or thymidine analogs AZT and Zerir ; --some clinicians are avoiding those when possible because of implication in lipoatrophy. The wasting of "AZT butt" could be irreversible or take a long time to rebuild. If you are on it though, don't worry--Combivir is still an effective combination. the field, and there appears to be some "turf-war" tension going on out there among the companies for share of the market. This has resulted in some not so subtle jabs at the competitors. Note to companies: "As the community we urge you to stop behaving like children. When your drugs are good, they will speak for themselves. Please stick to selling your own drugs rather than trying to trash the competitors. It really does look silly. Now pick up your dollies and play nice." --Cathy Olufs.

Table 8. Addressing Tobacco in Managed Care: Comparison of Full Coverage of Key Antismoking Benefits, 1997 vs. 2000 14.

Xero-Lube saliva substitutes ; oral, spray Xopenex HFA levalbuterol ; inhalation, aerosol with adapter X-Prep senna ; oral, syrup Xylocaine HCl lidocaine ; injectable, solution Xylocaine HCl For Spinal lidocaine ; injectable, solution Xylocaine Jelly lidocaine topical ; topical, gel with applicator Xylocaine Topical lidocaine topical ; topical, ointment; topical, solution Xylocaine Viscous lidocaine topical ; mucous membrane, solution Xylose d-xylose ; oral, powder for reconstitution Yutopar ritodrine ; intravenous, solution Zanosar streptozocin ; intravenous, powder for injection * RESTRICTED TO MEDICAL REFERRAL CENTERS * Zantac ranitidine ; injectable, solution; intravenous, solution; oral, syrup Xanax, Zofran, Zyrtec Zaroxolyn metolazone ; oral, tablet Zyprexa Zerit stavudine ; oral, capsule; oral, powder for reconstitution Zestril * PHYSICIAN INITIATION ONLY * * HIV MEDICATION DISTRIBUTION RESTRICTION * Zerit XR stavudine ; oral, capsule, extended release * PHYSICIAN INITIATION ONLY * * HIV MEDICATION DISTRIBUTION RESTRICTION * Zestril lisinopril ; oral, tablet Vistaril, Zerit, Zetia, Zocor, Zyrtec * NOT APPROVED FOR TWICE DAILY DOSING * Ziagen abacavir ; oral, solution; oral, tablet * PHYSICIAN INITIATION ONLY * * HIV MEDICATION DISTRIBUTION RESTRICTION * * FDA MEDICATION GUIDE REQUIRED WITH EACH PRESCRIPTION DISPENSING: : fda.gov cder Offices ODS labeling * zidovudine intravenous, solution; oral, syrup; oral, capsule; oral, tablet lamivudine, zidovudine-lamivudine, ziprasidone * PHYSICIAN INITIATION ONLY * * HIV MEDICATION DISTRIBUTION RESTRICTION * zidovudine-lamivudine lamivudine-zidovudine ; oral, tablet zidovudine * PHYSICIAN INITIATION ONLY * * HIV MEDICATION DISTRIBUTION RESTRICTION * zinc oxide topical topical, ointment; topical, cream ziprasidone oral, capsule zidovudine * INJECTION NOT APPROVED. Capsules: 15 mg, DIN 02216086 20 mg, DIN 02216094 30 mg, DIN 02216108 40 mg beige ; , DIN 02216116 Zerit XR sustained release capsules: 37.5 mg, DIN 02247912 50 mg, DIN 02247913 75 mg, DIN 02247914 100 mg, DIN 02247915 Oral solution: 1 mg ml fruit-flavoured solution 200 ml bottle stable for 30 days in fridge. Shake well. Refrigerate oral suspension; capsules stable at room temperature and leukeran. 210 ; 1108056 220 ; 10 April 2006 730 ; Fred Hosking Pty. Limited ACN ARBN 000 043 498 of Station Avenue CONCORD WEST NSW 2138, AUSTRALIA AU ; . 750 ; Finn Roache Solicitors Level 4 88 George Street SYDNEY NSW 2000 511 ; 510.
Let your doctor know if you have ever had peripheral neuropathy, because this condition occurs more often in patients who have had it previously. Peripheral neuropathy is also more likely to occur in patients taking drugs that affect the nerves and in patients with advanced HIV disease, but it can occur at any disease stage. If you develop peripheral neuropathy, your doctor may tell you to stop taking ZERIT XR. In some cases the symptoms worsen for a short time before getting better. Your and viramune. MATERIALS AND METHODS Study design. Novavir was a randomized, multicenter open-label trial that compared the safety and the efficacy of d4T versus AZT in combination with 3TC-IDV in HIV type 1 HIV-1 ; -infected patients pretreated with AZT, ddI, and or ddC but naive for d4T, 3TC, and PIs. Randomization was performed centrally in a 1: ratio, with stratification according to the number of copies of HIV-1 RNA in the plasma at the time of screening 10, 000 or less versus 10, 000 or more copies ml ; . Patients who completed 80 weeks of study were allowed to continue in an extension phase for an additional 12-month period. Approval was obtained from the Investigational Review Board at the site of the main investigator V.J. ; on 21 February 1997, and patients gave written informed consent. Treatment regimen. AZT Retrovir ; and 3TC Epivir ; were provided by Glaxo Wellcome, d4T Zerit ; was provided by Bristol-Myers Squibb, and IDV Crivixan ; was provided by Merck and Co. AZT was given as 250 to 300 mg twice daily, 3TC was given as 150 mg twice daily, d4T was given as 40 mg twice daily 30 mg for patients weighing 60 kg ; , and IDV was given as 800 mg every 8 h. Patients were advised to take IDV on an empty stomach. Study population. Enrolled patients had documented HIV-1 infection as determined by positive enzyme-linked immunosorbent assay and confirmed by Western blotting, were aged 18 years or older, and had 6 months of prior AZT, ddI, and or ddC cumulative treatment, either as monotherapy or in combination. Patients had HIV-1 plasma RNA levels of between 5, 000 and 200, 000 copies ml. Exclusion criteria included previous treatment with d4T, 3TC, or PIs; previous intolerance to AZT; investigational drugs within 60 days of study entry; opportunistic infection within 30 days of study entry; chronic diarrhea; peripheral neuropathy of grade 2 from the AIDS Clinical Trials Group toxicity scale, and pregnancy or breastfeeding. Patients with a hemoglobin level of 8.0 g dl, an absolute neutrophil count of 750 cells mm3, a platelet count of 75, 000 mm3, an aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase level 5 times the upper limit of normal ULN ; , an amylase level 2 times the ULN, a creatinine level 1.5 times the ULN, or a uric acid level 2 times the ULN were also excluded. Evaluation of patients. The patients were evaluated at screening day 28 ; , at randomization, at weeks 4 and 8, and every 8 weeks thereafter with a clinical assessment and routine laboratory monitoring. CD4 and CD8 cell counts and real-time plasma HIV RNA levels were determined at screening, baseline, weeks 4 and 8, and then every 16 weeks thereafter. In addition, plasma samples were stored at time of clinical assessment, i.e., every 8 weeks, allowing for retrospective batched determination of viral load. HIV RNA assays were performed at each site with the method routinely used at the time of the trial: bDNA Chiron; lower limit of detection, 500 copies ml ; in 8 laboratories, Amplicor HIV-1 Monitor assay Roche Molecular Systems; lower limit of detection, 200 copies ml ; in 28 laboratories, and both assays in 2 laboratories. All participating laboratories were members of the quality control Agence Nationale de Recherche sur le SIDA virology network. An ultrasensitive HIV-1 RNA PCR assay Roche; lower limit of detection, 50 copies ml ; was performed centrally on plasma samples obtained at weeks 8, 16, and 24. Mutation genotypic resistance studies were performed on viral plasma RNA collected at baseline day 0 ; , by the consensus technique of the Agence Nationale de Recherche sur le SIDA 21 ; . Primary and secondary RT mutations were identified according to the consensus statement from the International AIDS Society Resistance Testing-USA panel 10 ; . The study was reviewed twice by a data and safety monitoring board. At the second review, the data and safety monitoring board recommended continuing the follow-up of patients with HIV-1 RNA levels of 5, 000 copies ml every 3 months for 12 months. Endpoints. The primary measure of antiretroviral activity was the time to virological failure, defined as the first HIV RNA level of 5, 000 copies ml after at least 8 weeks of therapy, confirmed in a second specimen. The cutoff value of 5, 000 copies ml was retained since, when the trial was initiated, there were few options for salvage therapy in patients failing a PI-containing regimen. Sample size was calculated assuming that virological failure would be observed in 30% of patients in the less effective arm. Assuming that the more effective treatment would reduce the percentage of failing patients from 30 to 15%, a total of 157 patients per arm was required to establish a significant difference, in order to achieve 90% power at the 5% level of significance. Secondary outcome measures were grade 3 or grade 4 adverse events, AIDS-defining events or death, plasma HIV RNA and CD4 cell count changes, proportion of patients with less than 500 copies ml at week 80, and proportion of patients with less than 50 copies ml at weeks 8, 16, and 24.

Calculated on the basis of unadjusted least-squares mean methodology. Contrave Phase IIb Mean Weight Loss at 48 Weeks Completer Population and mysoline. Reason This drug is used for glaucoma, oedema and some forms of epilepsy. A medical decision is required to diagnose the disease and to establish the need for this drug. Proper medical supervision is also required during administration. This technique has been extensively described in the literature.1, 2, 14 19 When resting flows were established, FBF was measured during the last 2 minutes of 7-minute drug infusions. Drugs infused were acetylcholine 50 and 100 nmol min Novartis, Basel, Switzerland ; , sodium nitroprusside 12.6 and 37.8 nmol min Mayne Pharma, Leamington, Warks, UK ; , and finally coinfusion of vitamin C 25 mg ml with acetylcholine 50 and 100 nmol min for 7 minutes each at a constant rate of 1 ml min Graseby 3100 syringe pump ; . Each drug infusion period was separated by a washout period 10 to 30 minutes ; with 0.9% saline to allow flows to normalize. All FBF values were expressed as milliliters minute per 100 ml forearm tissue volume. This was converted to the ratio of the increase in blood flow between the infused arm and the blood flow in the control arm and expressed as a percentage change in FBF mean SEM ; , calculated according the method described by Whitney.20 The advantage of using noninfused arm data is that confounding effects on blood flow changes by external factors can be minimized.19 The disadvantage of this method is a possibility that the measurement error may be greater because the readings are taken from 2 separate arms. Blood pressure was measured by a semiautomated, noninvasive oscillometric sphygmomanometer Critikon Dinamap 1846 SX; Critikon, Tampa, Fla ; in the noninfused arm before each infusion period and at the conclusion of the study. Plasma levels of insulin DiaSorin, Wokingham, Berks, UK ; , PIIINP Oxford Biosystems Ltd, Oxford, UK ; , and BNP Bachem Ltd, St Helens, Merseyside, UK ; were all measured at our laboratory using radioimmunoassay and oxytrol. The features of neuropathic bladder dysfunction may be present without an overt neurological abnormality. Shah & Leach, 1998 ; . In these circumstances, a neurological problem should be considered and efforts made to uncover an as yet undiagnosed cause, such as Multiple Sclerosis, a spinal cord lesion or a tethered cord. INDICATION: ZERIT stavudine ; in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection. IMPORTANT SAFETY INFORMATION: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including ZERIT and other antiretrovirals. Fatal lactic acidosis has occurred in pregnant women receiving the combination of ZERIT and didanosine with other antiretrovirals. This combination should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk. Fatal and non-fatal pancreatitis have occurred during therapy when ZERIT was a part of a combination regimen that included didanosine, with or without hydroxyurea, in both treatment-nave and treatment-experienced patients, regardless of degree of immunosuppression. ZERIT should be suspended in suspected cases of pancreatitis. The safety and efficacy of ZERIT have not been established in HIV-infected patients with significant underlying liver disease. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered and topamax and Buy cheap zerit. File: Users dad Documents Green AIDS ARAS aras.ab test haart-integrated 67 of 156 ; 3 27 2006 PM.

For the people that have not had success with drugs or that have excessive side effects with them, and they're not good candidates for resective surgery, the Vagal Nerve Stimulation VNS ; is a very reasonable option to use. This is definitely a palliative therapy, meaning that very few people on the VNS will go seizure free. But there's a very good chance that seizures will become less severe and less frequent. VNS has shown that it reduces the amount of seizure activity quite dramatically once it's been used for several months. You might all be familiar with this, but it is consistent with placing a pacemaker, which is very similar to the device for people with cardiac disease . but instead of connecting to the heart the pacemaker connects through a wire to the left vagus nerve in the neck and atrovent.
Time Consuming It is concluded that the documentation of the indigenous knowledge on biodiversity is very time consuming process. One needs to give plenty of time to the informants in memorizing his her knowledge on the subject. Sometimes, the particular knowledge is not being in practiced during the field study; at the same time there may be chances to miss the knowledge to be documented. Hence, it is recommended that the study should be carried out through out the year i.e. all seasons for agricultural practices, all cultural and ritual ceremony and all festivals. g ; Capacity Building of the Local Indigenous Nationalities Institutions Indigenous Knowledge on biodiversity is crucial to the survival and subsistence of Nepal's Indigenous Nationalities as it provides the basis for food security, human and animal health and natural resource management. Therefore this precious knowledge has to be documented before it becomes extinct. It is recommended that all Nepalese Indigenous Nationalities have to be made selfaware of them about these assets that has been passed down from previous generations. For this, local Indigenous Nationalities Institution i.e. Rong Sejum Thi should have to play catalytic role to create awareness among all Lapcha community. In addition, institutions working to uplift Nepalese Indigenous Nationalities like Nepal Federation of Indigenous Nationalities NEFIN ; , National Foundation for Development of Indigenous Nationalities NFDIN ; and other donor development agencies should develop strategies to work through local Indigenous Nationalities Institution in this regard. h ; Scientific Research It is concluded that this study has documented many indigenous knowledge and practices of Lapcha community on biodiversity those are useful to all human beings. For example: a composition of different medicinal plants for curing fracture, Kukoor Tarul for sterilization, Tite Fapar; a curse to agricultural land and so on. However, they do not have any scientific evidence to justify them yet. Therefore, it is recommended that this useful knowledge should be further researched and tested scientifically in Laboratory, which will be useful to all human beings in days to come. Finally, Lapcha community will be able to claim patent rights over their knowledge.

Several key changes are proposed in the area of approval of generic pharmaceutical products. Where generic versions of medicinal products authorised by the centralised procedure i.e. for the most part, biotechnology The European Union EU ; pharmaceuproducts ; previously were required to tical regulatory system, the Mutual use the same approval route, under the Recognition Procedure MRP ; , was first new proposals, such generic products introduced in 1965 by Directive 65 may be authorised by the centralised and, after a series of amending procedure, the MRP or the decentralised directives, was later augmented by procedure. Further, under the abridged Regulation 2309 93 on 1 January 1995 marketing authoriwith the launch of the Under the proposed sation procedure centralised procedure. legislation, the through which After five years of most generic operation of the drugs are dual systems, the approved ; , the term European Commission for all new conducted an audit active substances. "essentially similar", of the procedures to be which has been the carried out, which has resulted in subject of so many referrals to the legislative proposals designed to adapt European Court of Justice ECJ ; on.
Identification of Drug Targets by Synchrotron Beam Line Maged Al-Sherbiny Faculty of Science, Cairo University, Cairo - Egypt Drug discovery research will target diseases of heavy burden on the Egyptian population such as Hepatitis C and Schistosomiasis. HCV is a 50 spherical, enveloped virus in the Flaviviridae family. The HCV genome, a single-stranded linear RNA of positive-sense, is ~9.5 kb in length, and is comprised of 5 and 3 non-coding regions and genes for core C ; , envelope 1 E1 ; , envelope 2 E2 ; , and nonstructural 2-5 NS2-NS5 ; proteins. Within an individual there are innumerable HCV variants that collectively comprise the HCV quasi species, and HCV from different people may have only 50-60% nucleic acid identity. Based upon this genetic heterogeneity, HCV strains can be divided into major groups, called genotypes. Types 1 and 2 predominate in the United States and Europe; type 4 is almost exclusively found in Egypt. Prevalence of antibodies to HCV anti-HCV ; in adult populations of developed countries is 1-2%; infection rates are higher in most developing countries. WHO estimates 3% of the world's population have been infected with HCV and that 170 million persons are chronic carriers. HCV RNA can usually be persistently detected in 85% of infected patients. ~20% of those with chronic HCV infections develop cirrhosis. Annual incidence of hepatocellular carcinoma HCC ; is 2 to 4% 20-30 year HCV carriers. Several reports during the past 5 years have documented that Egypt has the highest prevalence of HCV infection in the world, averaging 15-25% in rural communities. The prevalent 95% ; HCV genotype is type 4, which is rare in the USA and Europe. Our research on HCV will identify potential target proteins in hepatitis C virus from the dominant genotype in Egypt, namely "Genotype 4a". Then to express and produce drug target s ; in a recombinant protein form and produce purified protein crystals for evaluation by Synchrotron beam light to identify drug targets and possible therapeutic agents. This will lead to identification of possible interaction mechanisms between drug target s ; and suitable therapeutic agent s ; . Our potential HCV 4a targets include Internal Ribosome Entry Site IRES ; for host ribosome sequestration, NS3-4A enzyme of viral replication, NS5B polymerase of viral replication and Phosphatase enzyme class of signal transduction.

44. J Ophthalmol. 2001 Jul; 132 1 ; : 19-26. Use of vitamin supplements and cataract: the Blue Mountains Eye Study. Kuzniarz M, Mitchell P, Cumming RG, Flood VM. 45. J Physiol Gastrointest Liver Physiol. 2001 Jul; 281 1 ; : G144-50. Mechanism of thiamine uptake by human colonocytes: studies with cultured colonic.

Class: nucleoside analog also called nucleoside reverse transcriptase inhibitor, NRTI, or nuke ; Standard dose: DISCONTINUED? One 0.75 mg tablet three times a day, take on an empty stomach. Liquid available through compassionate use program. Take missed dose as soon as possible, but do not double up on your next dose. AWP: 3 month Manufacturer contact: Roche Pharmaceuticals, rocheusa , 1 800 ; 2827780 AIDS Treatment Information Service: 1 800 ; HIV0440 4480440 ; Potential side effects and toxicity: Peripheral neuropathy tingling, burning, numbness or pain in the hands or feet ; may go away once Hivid is stopped, but can be painful and permanently debilitating if not treated in time. Other side effects include headache, fever, skin eruptions, sores or swelling in the mouth, nausea, and pancreatitis. Rare but potentially fatal toxicity with all NRTIs is pancreatitis inflammation of the pancreas ; , hepatomegaly enlarged liver ; with steatosis and lactic acidosis accumulation of lactate in the blood and abnormal acid-base balance ; . Lactic acidosis has been seen in patients taking NRTIs but is more common and more severe in women, people who are obese and people who have been taking nukes for a long time; and more common in people with liver disease, but can occur in people without a history of liver damage. People with lactic acidosis may experience persistent fatigue, abdominal pain or distension, nausea vomiting, and difficulty breathing or shortness of breath; and enlarged, fatty liver called hepatomegaly with steatosis ; . People with a history of peripheral neuropathy, pancreatitis or heavy alcohol use should avoid Hivid. Pancreatitis can be life-threatening and may cause pain in the stomach and back, along with nausea, vomiting and blood in the urine. Your physician will check for pancreatitis by checking for increased levels of amylase and lipase in the blood. Risks for pancreatitis include: higher than recommended doses of NRTIs, advanced HIV, and alcohol use. Body fat redistribution accumulation has also been reported with Hivid. With few exceptions, these side effects are stronger than is seen with other NRTIs. Potential drug interactions: Due to increased risks associated with peripheral neuropathy, Hivid should not be taken with Videx ddI ; or Zerit d4T ; . Epivir 3TC ; and Emtriva FTC ; should also be avoided as they can lower the levels of Hivid in the body. Other medications that can interact with Hivid include Antabuse disulfi ram ; , Fungizone amphotericin B ; , Benemid probenecid ; , Chloromycetin chloramphenicol ; , certain chemotherapy agents, Dilantin phenytoin ; , dapsone, Foscavir foscarnet ; , isoniazid, Flagyl metronidazole ; , hydralazine, ribavirin, and Macrodantin Macrobid nitrofurantoin ; . When used at the same time as Tagamet cimetidine ; and Benemid probenecid ; monitor for renal toxicity. Maalox and Foscavir may decrease Hivid levels. When used with Hivid, pentamidine NebuPent, Pentam or Pentacarinat, used for treating Pneumocystis jiroveci pneumonia PCP ; , may increase risk of pancreatitis. Hivid should not be taken at the same time with antacids containing magnesium or aluminum, as they may decrease levels of Hivid in the body. Tips: Is expected to be taken off the market in 2006, due to rare use, lack of potency and side effects. For a long time rarely used, Hivid is being prescribed more in salvage therapy. Hivid should be avoided if you are pregnant or breast feeding and buy copegus. Because stavudine is not protein-bound, it is not expected to affect the pharmacokinetics of proteinbound drugs. Tables 5 and 6 summarize the effects on AUC and Cmax, with a 95% confidence interval CI ; when available, following coadministration of ZERIT stavudine ; with didanosine, lamivudine, and nelfinavir. No clinically significant pharmacokinetic interactions were observed. Table 5: Results of Drug Interaction Studies with ZERIT: Effects of Coadministered Drug on Stavudine Plasma AUC and Cmax Values Drug Stavudine Dosage na AUC of Stavudine 95% CI ; Cmax of Stavudine 95% CI ; 17% 12% 100.3-126.1.

Zerit capsules

Zerit malpractice

Zerit and dose, d4t zerit, zerit capsules, zerit malpractice and where to buy zerit. Zerit ndc, zerit viread, buy generic zerit and zerit capsule or discount zerit.

Where to buy Zerit

Tuberculin deficiency, reduction mammaplasty images, locus valley golf, medicaments names and hurler syndrome kids. 1918 spanish flu history, trimox diet, ischemia on ecg and primidone pain or hernia hiatal mexico.